



What partners of the “**Multi-site Efficacy and Safety Trial of Intrapartum Azithromycin in Low- and Middle-Income Countries (A-Plus)**” project are saying

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

“We urgently need effective interventions to reduce the death toll of pregnancy-related infections worldwide. This study allows us to test a low-cost intervention that has shown promise in a smaller study.”

Diana W. Bianchi, M.D., NICHD Director

Foundation for the National Institutes of Health (FNIH)

“The A-Plus study of azithromycin in prevention of sepsis represents vital research to improve the lives of women and children in low- and middle-income countries. The FNIH is pleased to work with NICHD’s Global Network for Women’s and Children’s Health Research and a multitude of partners on this important project.”

Stephanie James, Ph.D., Senior Vice President of Science, Foundation for the National Institutes of Health

Indiana University with Moi University (Kenya)

“Maternal and neonatal sepsis are a serious threat to health and well-being in sub-Saharan Africa. The GN-Kenya site advocates for quality health care to save lives through research. We are therefore excited to participate in this important study to investigate a potentially effective and affordable intervention to reduce mortality from sepsis.”

Fabian Esamai, MBChB, MMed, MPH, Ph.D., Principal of Alupe University College and Senior Foreign Investigator of the Indiana-Moi University Kenya site

Thomas Jefferson University with the Department of Medical Education, Jawaharal Nehru Medical College (Belagavi, India)

“The A-Plus trial will help prevent infection and save lives of mothers and newborns.”

Dr. Avinash Kavi, MD, DNB, FDIAB, MIPHA, Assistant Professor, Department of Community Medicine, Jawaharal Nehru Medical College, KLE Academy of Higher Education & Research, Belagavi, India

University of Alabama at Birmingham with University of Zambia Department of Paediatrics & Child Health University Teaching Hospital (Zambia)

“The A-Plus trial will be a pivotal study, as it will conclusively determine whether a single intra-partum oral dose of azithromycin reduces death or infection in mothers and their newborn babies in low-resource settings.”

Wally Carlo, M.D., Edwin M. Dixon Professor of Pediatrics; Director, Division of Neonatology and Director, Newborn Nurseries, University of Alabama at Birmingham

University of North Carolina at Chapel Hill with the Kinshasa School of Public Health (Democratic Republic of Congo)

“Because of the risk of death from infection, pregnancy and childbirth are frightening for women in developing countries. We are pleased to participate with our colleagues in the Democratic Republic of Congo, and around the world, in this very important study, a study that promises to make a difference in the lives of these women and their newborns.”

Carl Bose, M.D., Professor of Pediatrics and Member of the UNC Institute for Global Health & Infectious Diseases, University of North Carolina School of Medicine

University of Virginia with the International Center for Diarrhoeal Disease Research (Bangladesh)

“Azithromycin is a remarkable antibiotic and has proven useful, even life-saving, for child health in resource-limited settings. Here in the A-Plus project it is being tested to see whether it can reduce maternal and neonatal infections or death during childbirth. This would be a very practical, important and scalable finding that could dramatically improve health outcomes for the most vulnerable.”

Eric Houpt, M.D., Chief, Division of Infectious Diseases and International Health, University of Virginia School of Medicine